Triple Negative Breast Cancer
Showing NaN - NaN of 39
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,
Recruiting
- Triple Negative Breast Cancer
- PD-L1 Negative
- Sacituzumab Govitecan-hziy
- +4 more
-
Anchorage, Alaska
- +231 more
Jan 17, 2023
Triple Negative Breast Cancer, PD-L1 Positive Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Pembrolizumab,
Recruiting
- Triple Negative Breast Cancer
- PD-L1 Positive
- Sacituzumab Govitecan-hziy
- +5 more
-
Anchorage, Alaska
- +245 more
Jan 12, 2023
NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)
Recruiting
- Non-small Cell Lung Cancer
- +11 more
-
Birmingham, Alabama
- +32 more
Jan 4, 2023
Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)
Active, not recruiting
- Melanoma
- +7 more
- Autogene cevumeran
- Atezolizumab
-
Scottsdale, Arizona
- +36 more
Dec 22, 2022
Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin)
Active, not recruiting
- Triple Negative Breast Cancer
- Atezolizumab
- +3 more
-
Concord, California
- +429 more
Dec 12, 2022
Non Small Cell Lung Cancer, Urothelial Cancer, Ovarian Cancer Trial in United States (XB002, Nivolumab)
Recruiting
- Non Small Cell Lung Cancer
- +9 more
- XB002
- +2 more
-
Saint Louis, Missouri
- +4 more
Dec 12, 2022
Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative Trial in United States (Atezolizumab, Carboplatin,
Active, not recruiting
- Triple Negative Breast Cancer
- +3 more
- Atezolizumab
- +3 more
-
Washington, District of Columbia
- +5 more
Dec 1, 2022
Squamous Cell Carcinoma of Head and Neck, NSCLC, Hepatocellular Carcinoma Trial in Worldwide (KY1044, KY1044 and atezolizumab)
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- +11 more
- KY1044
- KY1044 and atezolizumab
-
New Haven, Connecticut
- +12 more
Nov 3, 2022
Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal
Recruiting
- Breast Cancer
- +15 more
- ATRC-101
- +2 more
-
Phoenix, Arizona
- +10 more
Sep 28, 2022
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma Trial in United Kingdom, United States
Terminated
- Pancreatic Adenocarcinoma
- +13 more
- GB1275
- +2 more
-
San Francisco, California
- +7 more
Aug 17, 2022
Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer Trial in United States (navicixizumab+paclitaxel,
Recruiting
- Colorectal Cancer
- +3 more
- navicixizumab+paclitaxel
- +2 more
-
Hot Springs, Arkansas
- +5 more
Aug 9, 2022
NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- CPI-006
- +2 more
-
Tucson, Arizona
- +26 more
Aug 1, 2022
NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +5 more
- CART-TnMUC1
- +2 more
-
Phoenix, Arizona
- +9 more
Jul 18, 2022
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant Trial in Bethesda, Nashville (TC-510, Fludarabine,
Recruiting
- Mesothelioma
- +14 more
- TC-510
- +2 more
-
Nashville, TennesseeSarah Cannon Research Institute
Jul 14, 2022
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,
Recruiting
- Any Advanced Solid Tumors
- +6 more
-
Tampa, Florida
- +7 more
Jul 13, 2022
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in Japan, United States (Datopotamab
Recruiting
- Hormone Receptor Positive Breast Cancer
- +2 more
- Datopotamab Deruxtecan (Dato-DXd)
-
Los Angeles, California
- +13 more
Jun 21, 2022
Breast Cancer, Triple Negative Breast Cancer, Residual Cancer Trial in United States (Atezolizumab, Sacituzumab govitecan)
Recruiting
- Breast Cancer
- +3 more
- Atezolizumab
- Sacituzumab govitecan
-
San Francisco, California
- +8 more
May 25, 2022
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY314, Combination Therapy: PY314 +
Recruiting
- Advanced Solid Tumor
- +8 more
- PY314
- Combination Therapy: PY314 + Pembrolizumab
-
Scottsdale, Arizona
- +12 more
Mar 28, 2022